| |
Adjusted OR (95 % CI) any fracture
|
Adjusted OR (95 % CI) accidental fracture
|
Adjusted OR (95 % CI) hip fracture
|
|---|
|
ADT
a
|
|
No
|
1.0 (Reference)
|
1.0 (Reference)
|
1.0 (Reference)
|
|
Yes
|
2.83 (2.52–3.17)
|
1.47 (1.28–1.68)
|
1.82 (1.44–2.30)
|
|
Extent of disease
a
|
|
Localised
|
|
No ADT
|
1.0 (Reference)
|
1.0 (Reference)
|
1.0 (Reference)
|
|
ADT
|
3.42 (1.70–6.88)
|
1.85 (0.72–4.74)
|
6.56 (1.32–32.64)
|
|
Locally advanced or Metastatic
|
|
No ADT
|
1.0 (Reference)
|
1.0 (Reference)
|
1.0 (Reference)
|
|
ADT
|
3.73 (2.83–4.91)
|
1.38 (0.94–2.05)
|
3.43 (1.44–8.19)
|
|
Unknown
|
|
No ADT
|
1.0 (Reference)
|
1.0 (Reference)
|
1.0 (Reference)
|
|
ADT
|
2.21 (1.93–2.52)
|
1.40 (1.20–1.63)
|
1.60 (1.25–2.06)
|
|
Age
b
|
|
< 65
|
|
No ADT
|
1.0 (Reference)
|
1.0 (Reference)
|
1.0 (Reference)
|
|
ADT
|
4.67 (3.76–5.81)
|
1.50 (1.10–2.05)
|
2.02 (0.93–4.39)
|
|
≥ 65
|
|
No ADT
|
1.0 (Reference)
|
1.0 (Reference)
|
1.0 (Reference)
|
|
ADT
|
2.89 (2.55–3.29)
|
1.87 (1.61–2.17)
|
2.53 (1.99–3.22)
|
- ADT androgen deprivation therapy, OR odds ratio, CI confidence interval
- aAdjusted for age of diagnosis and ethnicity
- bAdjusted for ethnicity
- Bold indicate significant p-value (<0.5)
